InflaRx (Nasdaq: IFRX) will participate in the Raymond James 2026 Biotech Innovation Symposium in New York on April 14, 2026. The company will hold one-on-one investor meetings and present its pipeline highlights, including izicopan and vilobelimab, and corporate overview.
Contact details for investor relations and media are provided.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – IFRX
+7.54%
3 alerts
+7.54%Session close to close
-5.3%Trough Tracked
$64.66MMarket Cap
0.2xRel. Volume
In the Mar 31 session, IFRX gained 7.54%, reflecting a notable positive market reaction.
Argus tracked a trough of -5.3% from its starting point during tracking.
Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
The stock moved +7.5% in the session following this news. A strong positive reaction aligns with Inf...
Analysis
The stock moved +7.5% in the session following this news. A strong positive reaction aligns with InflaRx’s focus on visibility and investor outreach. Prior events show share-price sensitivity to clinical and earnings updates, while conference news has had mixed impact. A large move after this symposium announcement would have reflected changing sentiment toward the pipeline and balance sheet, including the recent €45.6 million annual net loss and dependence on izicopan and vilobelimab progress.
Participation in Leerink Global Healthcare Conference with fireside chat and 1x1s.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news shows mixed alignment: earnings and clinical updates sometimes align with price moves, while conference and presentation news often see divergent or muted reactions.
Recent Company History
Over recent months, InflaRx has focused on clinical and investor-facing milestones. A Mar 19 full-year 2025 update highlighted positive Phase 2a izicopan data and funding into mid‑2027. Multiple March announcements covered vilobelimab Phase 3 data and AAD presentations, with a Mar 30 update noting early trial termination for futility despite some efficacy signals. Conference participation, such as the Feb 26 Leerink event and the new Raymond James symposium appearance, underscores ongoing investor outreach alongside clinical development.
Key Terms
complement system, anti-c5a, anti-c5ar, c5a receptor, +4 more
8 terms
complement systemmedical
"pioneering anti-inflammatory therapeutics by targeting the complement system"
The complement system is a set of proteins in the blood that act together like a security alarm and cleanup crew for the body’s immune system: they detect threats, tag invaders for removal, and help destroy harmful cells. Investors should care because drugs or diagnostics that target or measure this system can affect treatment effectiveness, safety profiles, and market potential for therapies in immune, inflammatory, and rare disease areas.
anti-c5amedical
"applying its proprietary anti-C5a and anti-C5aR technologies to discover"
Anti-C5a is an antibody or small-molecule drug that blocks C5a, a naturally occurring protein that can trigger intense inflammation as part of the immune response; by neutralizing C5a the therapy aims to reduce harmful immune overreactions. For investors, anti-C5a candidates matter because positive clinical results can create new treatments for severe infections, autoimmune flares or inflammation-driven conditions, affecting a developer’s regulatory milestones, market potential and stock value—think of it as a medical brake on runaway inflammation.
anti-c5armedical
"applying its proprietary anti-C5a and anti-C5aR technologies to discover"
Anti-C5aR are drugs—often engineered antibodies or small molecules—that block the C5a receptor on immune cells, preventing a powerful immune signal (C5a) from triggering excessive inflammation. For investors, these therapies matter because they aim to calm harmful immune overreactions in conditions like severe infections or autoimmune diseases; success or failure in clinical trials and regulatory review greatly affects a drug’s commercial potential, development risk, and company valuation.
c5a receptormedical
"inhibitors of the complement activation factor C5a and its receptor, C5aR."
A C5a receptor is a protein on certain immune cells that senses the inflammatory signal called C5a, acting like a doorbell that summons and activates immune responders at sites of injury or infection. Investors care because drugs that block or modify this receptor can dial down damaging inflammation seen in conditions such as autoimmune disease, sepsis, or some lung disorders, making it a common target in pharmaceutical development and a potential value driver in drug pipelines.
pk/pdmedical
"has shown promising PK/PD characteristics as well as therapeutic potential"
PK/PD stands for pharmacokinetics and pharmacodynamics: PK describes how a drug moves through the body — how it is absorbed, distributed, broken down and eliminated — while PD describes the drug’s effects on the body and how those effects change with dose. For investors, strong PK/PD data help predict whether a drug can be dosed safely and effectively, shape clinical trial success, regulatory approval chances and commercial potential, much like knowing both delivery speed and the strength of a message before choosing a shipping method.
monoclonal antibodymedical
"vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody"
A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.
phase 1medical
"therapeutic potential in Phase 1 and Phase 2a clinical studies."
Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.
phase 2amedical
"therapeutic potential in Phase 1 and Phase 2a clinical studies."
Phase 2a is an early stage in testing a new medical treatment or drug, where the main goal is to assess its safety and find the right dosage. For investors, this stage indicates whether the treatment shows initial promise before moving on to larger, more definitive studies; progress here can influence expectations for future development and potential success.
JENA, Germany, March 31, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in the Raymond James 2026 Biotech Innovation Symposium. Details are as follows:
Raymond James 2026 Biotech Innovation Symposium April 14, 2026, in New York, NY The Company will hold one-on-one investor meetings.
About InflaRx InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx‘s lead program is izicopan (INF904), an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The Company is developing izicopan for the treatment of several inflammatory diseases, including hidradenitis suppurativa. The Company has also developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.
InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).
Contacts:
InflaRx N.V.
MC Services AG
Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de
Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752
FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading “Risk factors” and “Cautionary statement regarding forward looking statements” in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
FAQ
When will InflaRx (IFRX) participate in the Raymond James 2026 Biotech Innovation Symposium?
InflaRx will participate on April 14, 2026, holding one-on-one investor meetings. According to InflaRx, the company will be available for investor meetings in New York during the Raymond James 2026 Biotech Innovation Symposium to discuss its pipeline and strategy.
What programs will InflaRx (IFRX) highlight at the April 14, 2026 symposium?
InflaRx plans to highlight its lead programs izicopan and vilobelimab during investor meetings. According to InflaRx, discussions will focus on izicopan's oral C5aR inhibition and vilobelimab's anti-C5a antibody data and clinical development plans.
How can investors arrange one-on-one meetings with InflaRx (IFRX) at the symposium?
Investors can request one-on-one meetings through InflaRx investor relations contacts provided in the announcement. According to InflaRx, interested parties should use the listed IR email or MC Services AG contact details to schedule meetings ahead of April 14, 2026.
Will InflaRx (IFRX) provide clinical updates at the Raymond James 2026 Biotech Innovation Symposium?
The company will discuss clinical programs during meetings but no public session is specified. According to InflaRx, investor meetings may cover clinical data and program status for izicopan and vilobelimab, but no public presentation date was announced.
Where are InflaRx (IFRX) investor relations contacts located and how can they be reached?
InflaRx lists investor relations contacts in Germany and the U.S. with email and phone numbers. According to InflaRx, IR inquiries can be sent to IR@inflarx.de or inflarx@mc-services.eu and by phone to the provided Europe and U.S. numbers.
